Order Article Reprints

Leroux-Roels I, Bruhwyler J, Stergiou L, Sumeray M, Joye J, Maes C, Lambert P-H, Leroux-Roels G. Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines. 2023; 11(2):367. https://doi.org/10.3390/vaccines11020367

Leroux-Roels, Isabel, Jacques Bruhwyler, Lilli Stergiou, Mark Sumeray, Jasper Joye, Cathy Maes, Paul-Henri Lambert, and Geert Leroux-Roels. 2023. "Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine" Vaccines 11, no. 2: 367. https://doi.org/10.3390/vaccines11020367

Leroux-Roels, I., Bruhwyler, J., Stergiou, L., Sumeray, M., Joye, J., Maes, C., Lambert, P.-H., & Leroux-Roels, G. (2023). Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines, 11(2), 367. https://doi.org/10.3390/vaccines11020367